文献速递心力衰竭与心肌病冠心病血脂与心血管预防

SGLT2抑制剂心肾获益机制再分析:营养剥夺信号与自噬假说的重申

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
PubMed 文献 · Circulation · 2022-10-31

本文重新分析了SGLT2抑制剂心肾获益的机制,认为其独特获益模式可通过促进自噬流解释,与同时上调营养剥夺信号(AMPK、SIRT1/3/6、PGC1-α)和下调营养过剩信号(mTOR)有关。抑制自噬、AMPK或sirtuins可消除这些保护效应,临床蛋白质组学和生物标志物研究支持该假说。

要点

  • SGLT2抑制剂心肾保护与增强自噬流及营养剥夺信号上调相关。
  • 抑制自噬、AMPK或sirtuins可消除SGLT2抑制剂的保护效应。
  • 临床蛋白质组学及酮体、红细胞增多、尿酸降低等标志物支持该假说。

核心结论

  • SGLT2抑制剂的心肾保护作用可由其促进自噬流、上调营养剥夺信号并下调营养过剩信号的机制解释。

研究设计与样本

  • 本文为机制综述与再分析,未报告系统检索范围或样本量。

主要发现

  • SGLT2抑制剂减少氧化应激和内质网应激、恢复线粒体健康、减少促炎和促纤维化通路并保持细胞完整性。
  • SGLT2抑制剂上调AMPK、SIRT1、SIRT3、SIRT6和PGC1-α表达与活性,并降低mTOR激活。
  • 特异性抑制或敲低自噬、AMPK和sirtuins可消除SGLT2抑制剂的心肾保护效应。
  • 随机试验血液蛋白质组学显示差异增加的蛋白质模式与上述发现一致。
  • 临床研究显示SGLT2抑制剂促进糖异生、生酮和红细胞增多并降低尿酸血症,这些是营养剥夺信号标志及降低心衰和严重肾脏事件风险的主要统计中介因素。

临床怎么用

  • 临床可依据营养剥夺信号标志物(如酮体、红细胞增多、尿酸降低)理解SGLT2抑制剂的心肾获益。

局限性

  • 原文未报告系统检索范围或纳入研究数量。
  • 原文指出肾脏或心血管生理或代谢变化不能解释SGLT2抑制剂的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in oxidative and endoplasmic reticulum stress, restoration of mitochondrial health and enhanced mitochondrial biogenesis, a decrease in proinflammatory and profibrotic pathways, and preservation of cellular and organ integrity and viability. A substantial body of evidence indicates that this characteristic pattern of responses can be explained by the action of SGLT2 inhibitors to promote cellular housekeeping by enhancing autophagic flux, an effect that may be related to the action of these drugs to produce simultaneous upregulation of nutrient deprivation signaling and downregulation of nutrient surplus signaling, as manifested by an increase in the expression and activity of AMPK (adenosine monophosphate-activated protein kinase), SIRT1 (sirtuin 1), SIRT3 (sirtuin 3), SIRT6 (sirtuin 6), and PGC1-α (peroxisome proliferator-activated receptor γ coactivator 1-α) and decreased activation of mTOR (mammalian target of rapamycin). The distinctive pattern of cardioprotective and renoprotective effects of SGLT2 inhibitors is abolished by specific inhibition or knockdown of autophagy, AMPK, and sirtuins. In the clinical setting, the pattern of differentially increased proteins identified in proteomics analyses of blood collected in randomized trials is consistent with these findings. Clinical studies have also shown that SGLT2 inhibitors promote gluconeogenesis, ketogenesis, and erythrocytosis and reduce uricemia, the hallmarks of nutrient deprivation signaling and the principal statistical mediators of the ability of SGLT2 inhibitors to reduce the risk of heart failure and serious renal events. The action of SGLT2 inhibitors to augment autophagic flux is seen in isolated cells and tissues that do not express SGLT2 and are not exposed to changes in environmental glucose or ketones and may be related to an ability of these drugs to bind directly to sirtuins or mTOR. Changes in renal or cardiovascular physiology or metabolism cannot explain the benefits of SGLT2 inhibitors either experimentally or clinically. The direct molecular effects of SGLT2 inhibitors in isolated cells are consistent with the concept that SGLT2 acts as a nutrient surplus sensor, and thus, its inhibition causes enhanced nutrient deprivation signaling and its attendant cytoprotective effects, which can be abolished by specific inhibition or knockdown of AMPK, sirtuins, and autophagic flux.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis. Circulation. 2022. PMID: 36315602. doi:10.1161/CIRCULATIONAHA.122.061732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。